From each FDA label

Do GLP-1s cause nausea?

Nausea is in the main trial table of 9 labels. The highest rate printed is 44% on Wegovy 2.4 mg (16% on placebo) and the lowest 18% on Mounjaro 15 mg (4% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Rate against placebo

How often nausea happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

Medicine	Dose	On it	On placebo	Difference	Label
Wegovy	2.4 mg	44%	16%	+28 points	DailyMed
Saxenda	3 mg	39.3%	13.8%	+25.5 points	DailyMed
Foundayo	17.2 mg	35%	10%	+25 points	DailyMed
Zepbound	15 mg	28%	8%	+20 points	DailyMed
Trulicity	1.5 mg	21.1%	5.3%	+15.8 points	DailyMed
Ozempic	1 mg	20.3%	6.1%	+14.2 points	DailyMed
Rybelsus and Ozempic tablets	14 mg	20%	6%	+14 points	DailyMed
Victoza	1.8 mg	20%	5%	+15 points	DailyMed
Mounjaro	15 mg	18%	4%	+14 points	DailyMed

Word for word

What each label says about nausea

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

The most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for Wegovy and placebo, respectively.
In clinical trials in adults for weight reduction, 73% of Wegovy injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving Wegovy injection (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%).
In the pediatric clinical trial for weight reduction, 62% of Wegovy injection-treated patients and 42% of placebo-treated patients reported gastrointestinal adverse reactions. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%).

Label revised Jun 18, 2026. DailyMed

Ozempic

The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.

Label revised Jun 1, 2026. DailyMed

Rybelsus and Ozempic tablets

The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation.

Label revised Jan 30, 2026. DailyMed

Zepbound

The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.

Label revised Aug 28, 2026. DailyMed

Mounjaro

The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.

Label revised Aug 27, 2026. DailyMed

Foundayo

The incidence of nausea, vomiting, and diarrhea was higher during the Foundayo dosage escalation period and decreased over time.

Label revised Jul 29, 2026. DailyMed

Saxenda

The most common adverse reactions leading to discontinuation were nausea (2.9% versus 0.2% for Saxenda and placebo, respectively), vomiting (1.7% versus less than 0.1%), and diarrhea (1.4% versus 0%).
In the adult clinical trials, approximately 68% of Saxenda-treated patients and 39% of placebo-treated patients reported gastrointestinal disorders; the most frequently reported was nausea (39% and 14% of patients treated with Saxenda and placebo, respectively).
There have been reports of gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, associated with volume depletion and renal impairment.
Most adverse reactions leading to discontinuation were due to vomiting and nausea (4.8% and 3.2% of Saxenda-treated patients, respectively).

Label revised Feb 25, 2026. DailyMed

Byetta

The most frequently reported adverse reaction associated with Byetta, nausea, occurred in a dose-dependent fashion.
With continued therapy, the frequency and severity decreased over time in most of the patients who initially experienced nausea.
The most common adverse reactions leading to withdrawal for Byetta-treated patients were nausea (3% of patients) and vomiting (1%).
For placebo-treated patients, <1% withdrew due to nausea and none due to vomiting.

Label revised Sep 2, 2025. DailyMed

Victoza: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Trulicity: no finding on this in the sections read here.

Not from trials

Reports to FDA about nausea

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

Medicine	Reports naming	All reports on it
Byetta	Nausea: 12,076	52,087
Trulicity	Nausea: 10,397	87,279
Ozempic	Nausea: 10,184	70,863
Mounjaro	Nausea: 9,837	97,440
Zepbound	Nausea: 9,576	80,835
Victoza	Nausea: 6,285	41,462
Wegovy	Nausea: 3,474	25,993
Saxenda	Nausea: 1,191	7,270
Rybelsus and Ozempic tablets	Nausea: 1,112	7,758
Foundayo	Nausea: 715	3,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Aug 28, 2026FDA labelFDA label updated: Zepbound (Eli Lilly and Company), effective 2026-08-28
Aug 27, 2026FDA labelFDA label updated: Mounjaro (Eli Lilly and Company), effective 2026-08-27
Jul 29, 2026FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29
Jul 27, 2026FDA labelFDA label updated: Liraglutide (Meitheal Pharmaceuticals Inc.), effective 2026-07-27
Jun 24, 2026FDA labelFDA label updated: Liraglutide (NorthStar Rx LLC), effective 2026-06-24

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Nausea on a GLP-1: common questions

Which GLP-1 causes the most nausea?

No trial here ranks them. By the rates each label prints, Wegovy 2.4 mg is highest at 44% (placebo 16%) and Mounjaro 15 mg lowest at 18% (placebo 4%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Wegovy cause nausea?

In its FDA label, 44% of people taking Wegovy 2.4 mg reported nausea, against 16% on placebo.

Does Saxenda cause nausea?

In its FDA label, 39.3% of people taking Saxenda 3 mg reported nausea, against 13.8% on placebo.

Does Foundayo cause nausea?

In its FDA label, 35% of people taking Foundayo 17.2 mg reported nausea, against 10% on placebo.

Does Zepbound cause nausea?

In its FDA label, 28% of people taking Zepbound 15 mg reported nausea, against 8% on placebo.

Does Trulicity cause nausea?

In its FDA label, 21.1% of people taking Trulicity 1.5 mg reported nausea, against 5.3% on placebo.

Does Ozempic cause nausea?

In its FDA label, 20.3% of people taking Ozempic 1 mg reported nausea, against 6.1% on placebo.

How long does nausea last on a GLP-1?

Labels describe when it happens, not how many days it lasts. Ozempic: "The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation." Rybelsus and Ozempic tablets: "The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation." Zepbound: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.